TR1 is known as the death receptor (DR4), TRAIL receptor 1 (TRAILR1), and tumor necrosis factor receptor superfamily member 10A (TNFRSF10A), which belongs to the superfamily of TFN-receptor. TR1 is associated with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), prostate cancer, bladder cancer, head and neck squamous-cell carcinoma (HNSCC), melanoma, renal carcinoma and ovarian carcinoma. TR1 transduces cell death signal and induce cell apoptosis through activated by tumor necrosis factor-related apoptosis inducing ligand.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE